Suppr超能文献

肿瘤干细胞在声门上型癌淋巴结转移中可能的作用。

The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma.

机构信息

Institute of Eye and ENT, Provincial Hospital affiliated to Shandong University, Jinan, 250021, People's Republic of China.

出版信息

Pathol Oncol Res. 2011 Mar;17(1):33-8. doi: 10.1007/s12253-010-9271-9. Epub 2010 Apr 21.

Abstract

Tumor stem cells (TSC), which are considered as likely candidates for the origin of cancer, are deduced to be responsible for tumor metastasis theoretically. We therefore investigated whether TSC were associated with lymph node metastasis in supraglottic carcinoma. Immunohistochemistry was performed for CD44, CD133, and LYVE-1 to detect TSC and lymphatic vessel density (LVD) in 66 primary supraglottic carcinoma tissue samples from 30 patients with lymph node metastasis (N+) and 36 patients without (N0). Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot were used to detect the expression of CD44 and CD133 at mRNA and protein levels in N+ and N0 primary tumors. The LVD was 22.4 ± 10.26 in 30N+ and 6.8 ± 4.09 in 36N0 samples subjected to immunohistochemistry, which was associated with their clinical nodal stages. There were 43.33% CD44-positive and 93.33% CD133-positive samples in 30N +, and 13.89% CD44-positive and 44.44% CD133-positive samples in 36N0 (P < 0.05). However, in each positive slide, there were only 5∼10% CD44-positive cells, but 70∼85% CD133-possitive cells. The expressions of CD44 and CD133 of N+ obtained through RT-PCR and Western blot were significantly higher than those of N0. These results suggest that TSC identified through CD44-positive cells in N+ were significantly higher than those in N0, indicating that TSC may be responsible for lymph node metastasis. CD133, whose expression is not restricted to TSC, may be unspecific for TSC identification in hypostatic supraglottic carcinoma.

摘要

肿瘤干细胞(TSC)被认为是癌症起源的可能候选者,从理论上讲,它们被认为与肿瘤转移有关。因此,我们研究了 TSC 是否与声门上型癌的淋巴结转移有关。对 30 例有淋巴结转移(N+)和 36 例无淋巴结转移(N0)的患者的 66 例声门上型癌原发组织标本进行 CD44、CD133 和 LYVE-1 的免疫组织化学检测,以检测 TSC 和淋巴管密度(LVD)。逆转录聚合酶链反应(RT-PCR)和 Western blot 用于检测 N+和 N0 原发肿瘤中 CD44 和 CD133 的 mRNA 和蛋白水平的表达。免疫组织化学检测的 30 例 N+样本的 LVD 为 22.4±10.26,36 例 N0 样本的 LVD 为 6.8±4.09,与淋巴结临床分期有关。30 例 N+中有 43.33%的 CD44 阳性和 93.33%的 CD133 阳性,而 36 例 N0 中有 13.89%的 CD44 阳性和 44.44%的 CD133 阳性(P<0.05)。然而,在每个阳性切片中,只有 5∼10%的 CD44 阳性细胞,但有 70∼85%的 CD133 阳性细胞。通过 RT-PCR 和 Western blot 获得的 N+中 CD44 和 CD133 的表达明显高于 N0。这些结果表明,通过 N+中 CD44 阳性细胞鉴定的 TSC 明显高于 N0,表明 TSC 可能与淋巴结转移有关。CD133 的表达不受 TSC 限制,因此在实体性声门上型癌中,CD133 可能无法特异性识别 TSC。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验